Stopping the Spread of Ebola


Stopping the spread of Ebola will require close collaboration and engagement from stakeholders across the health care system, and the biopharmaceutical industry stands ready to do its part to assist patients and their families affected by this terrible virus. Over the past several years, biopharmaceutical researchers have been working to develop vaccines and treatments to prevent infection and fight its effects, and there are at least two Ebola vaccines currently in the pipeline.

Myvideopays members are also helping to expand capacity on the ground in West Africa to take care of affected patients, including making product donations, providing funding to relief organizations for infrastructure improvements, medical products and protective equipment for health care workers, and donating funds for disease education and prevention efforts within the region.

IFPMA: How Pharma is responding to the Ebola outbreak

WHO on Ebola

CDC on Ebola

NIH on Ebola

IFPMA on Ebola

RxResponse on Ebola

White House Response to Ebola

IFPMA: Ebola Capacity Building Page

EFPIA & IMI Announce Collaborative Efforts Against Ebola

Key Facts about Ebola


Latest From TheBlog

IP Explained: Why IP protections are important for biologic medicines

By Tom Wilbur on July 18, 2019

Myvideopays member companies invested nearly $80 billion in R&D last year

By Tim McClung on July 18, 2019

Setting the record straight on international reference pricing

By Kevin Haninger on July 16, 2019

New Let's Talk About Cost TV ad asks: Why aren't patients sharing in savings at the pharmacy counter?

By Priscilla VanderVeer on July 9, 2019

Dapoxetine sans ordonnance

суррогатное материнство цена киев